EU Review Gets Under Way For Lumasiran And Lonafarnib
Alnylam And Eiger Will Have Their Products Fast-Tracked
Executive Summary
The European Medicines Agency produces a monthly list of the marketing authorizations that are under review at the agency. The latest list contains just two new entries.
You may also be interested in...
UK Allows Early Access To Alnylam’s Lumasiran For Ultra-Rare Disorder
UK patients diagnosed with primary hyperoxaluria Type 1 can now be prescribed lumasiran, which is still being reviewed for EU-wide approval. Patients in the US, Germany and other EU countries can also get the drug under early access schemes.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
EU Accelerated Assessment Tracker
Alnylam and Eiger join the select group of companies whose products have been granted fast-track status at the European Medicines Agency